Poster Session 57

Prostate cancer: Is the future focal?

Poster Session 57

Sunday, 26 March
15:45 - 17:15

Location: Room Munich, North Hall (Level 1)

Chairs: E. Barret, Paris (FR)
B. Hollenbeck, Ann Arbor (US)
M. Valerio, Lausanne (CH)

Aims and objectives of this session
The aim of this session is to update delegates on the use of focal therapy and non-whole gland treatments.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

758

Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study
By: Shanmugabavan Y. 1, Bass E. 1, Hulme A. 2, Freeman A. 3, Brew-Graves C. 1, Potyka I. 1, Ramachandran N. 4, Emberton M. 1, Ahmed H.U. 1

Institutes: University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, 2Sophiris, Sophiris Bio Corporation, California, United States of America, 3University College London Hospital, Dept. of Histopathology, London, United Kingdom, 4University College London Hospital, Dept. of Radiology, London, United Kingdom

759

Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer
By: Potiron E. 1, Lacoste J. 2, Le Goguic G. 2, Rousseau T. 2, Nevoux P. 2

Institutes: Clinique Urologique Nantes Atlantis, Dept. of , Saint Herblain, France, 2Clinique Urologique Nantes Atlantis, Dept. of, Saint Herblain, France

760

Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy
By: Garcia Barreras S. 1, Sanchez-Salas R. 1, Sivararam A. 2, Secin F. 3, Redondo C. 1, Velilla G. 1, Barret E. 1, Nunes-Silva I. 1, Srougi V. 1, Baghdadi M. 1, Galiano M. 1, Rozet F. 1, Cathala N. 1, Mombet A. 1, Prapotnich D. 1, Cathelineau X. 1

Institutes: Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 2Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, 3CEMIC, Dept. of Urology, Buenos Aires, Argentina

761

A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

Institutes: Oxford University - Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 2Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 3University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, 4University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, 5Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, 6Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, 7University College London Hospital, Dept. of Urology, London, United Kingdom

762

First repeated biopsy represents the most informative predictor of progression-free survival at 3
A nomogram for prediction of local cancer recurrence after primary prostate cryoablation
By: El Shafei A. 1, Tay K.J. 2, Ross A. 3, Given R. 4, Parsons J.K. 5, Mouraviev V. 6, Polascik T. 2, Jones J.S. 1
Institutes: 1 Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2 Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 3 Johns Hopkins Medical Institutions, Dept. of Urology, Baltimore, United States of America, 4 Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 5 UC San Diego Health System, Dept. of Urology, San Diego, United States of America, 6 Global Robotics Institute, Dept. of Urology, Celebration, United States of America

Withdrawn

Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods
By: Miyata Y. 1, Mochizuki Y. 2, Shida Y. 3, Matsuo T. 1, Hakariya T. 1, Ohba K. 1, Furusato B. 2, Fukuoka J. 2, Sakai H. 1
Institutes: 1 Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, 2 Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

Salvage prostate cryoablation in older men
By: Parsons K. 2, Ross A. 3, El Shafei A. 1, Hatem A. 1, Cotta B. 2, Tay K.J. 4, Polascik T. 4, Given R. 5, Mouraviev V. 6, Jones J.S. 1
Institutes: 1 Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2 UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, 3 The Johns Hopkins Medical Institutions, Dept. of Urology, Baltimore, United States of America, 4 Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 5 Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 6 Global Robotics Institute, Dept. of Urology, Celebration, United States of America

Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit
By: Sujenthiran A. 1, Nossiter J. 2, Charman S. 3, Aggarwal A. 1, Cathcart P. 2, Payne H. 3, Clarke N. 4, Van Der Meulen J. 1
Institutes: 1 Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, 2 Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3 University College London Hospitals, Dept. of Oncology, London, United Kingdom, 4 The Christie and Salford Royal NHS Foundation Trus, Dept. of Urology, London, United Kingdom
MRI/US fusion office-based targeted cryoablation with local anesthesia
Institutes: Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

17:00 - 17:07

Summary

E. Barret, Paris (FR)